Literature DB >> 11357994

Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients.

E Kissinger1, T T Hien, N T Hung, N D Nam, N L Tuyen, B V Dinh, C Mann, N H Phu, P P Loc, J A Simpson, N J White, J J Farrar.   

Abstract

The qinghaosu (artemisinin) group of drugs is the most important new class of antimalarials developed in the last fifty years. Although there has been no clinical evidence of neurotoxicity, an unusual pattern of damage to specific brain-stem nuclei has been reported in experimental animals receiving high doses of arteether or artemether. Detailed clinical examinations, audiometry, and brain stem auditory evoked potentials (BSAEPs) were assessed in 242 Vietnamese subjects who had previously received up to 21 antimalarial treatment courses of artemisinin or artesunate alone and 108 controls from the same location who had not received these drugs. There was no evidence of a drug effect on the clinical or neurophysiological parameters assessed. In this population there was no clinical or neurophysiological evidence of brain-stem toxicity that could be attributed to exposure to artemisinin or artesunate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11357994     DOI: 10.4269/ajtmh.2000.63.48

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  16 in total

1.  Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether.

Authors:  Laurens Manning; Moses Laman; Madhu Page-Sharp; Sam Salman; Ilomo Hwaiwhanje; Namar Morep; Peter Siba; Ivo Mueller; Harin A Karunajeewa; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

2.  Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.

Authors:  Gabriel Carrasquilla; Clemencia Barón; Edwin M Monsell; Marc Cousin; Verena Walter; Gilbert Lefèvre; Oliver Sander; Laurel M Fisher
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

Review 3.  Artemisinins.

Authors:  C J Woodrow; R K Haynes; S Krishna
Journal:  Postgrad Med J       Date:  2005-02       Impact factor: 2.401

Review 4.  Artesunate versus quinine for treating severe malaria.

Authors:  David Sinclair; Sarah Donegan; Rachel Isba; David G Lalloo
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

Review 5.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 6.  Combination therapy for malaria: the way forward?

Authors:  François Nosten; Philippe Brasseur
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa.

Authors:  Ushma Mehta; David Durrheim; Aaron Mabuza; Lucille Blumberg; Elizabeth Allen; Karen I Barnes
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 8.  Usher syndrome IIIA: a review of the disorder and preclinical research advances in therapeutic approaches.

Authors:  Azmi Marouf; Benjamin Johnson; Kumar N Alagramam
Journal:  Hum Genet       Date:  2022-03-23       Impact factor: 4.132

9.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.

Authors:  Michael T Ambler; Lilly M Dubowitz; Ratree Arunjerdja; Eh Paw Hla; Kyaw Lay Thwai; Jacher Viladpainguen; Pratap Singhasivanon; Christine Luxemburger; François Nosten; Rose McGready
Journal:  Malar J       Date:  2009-09-02       Impact factor: 2.979

Review 10.  Safety profile of Coartem: the evidence base.

Authors:  Catherine Falade; Christine Manyando
Journal:  Malar J       Date:  2009-10-12       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.